

THE DESIGN OF NON-PEPTIDE HUMAN BRADYKININ B₂ RECEPTOR ANTAGONISTS EMPLOYING THE BENZODIAZEPINE PEPTIDOMIMETIC SCAFFOLD

Edward K. Dziadulewicz^{*,a}, Michael C. Brown^{a,†}, Andrew R. Dunstan^{a,‡},
Wai Lee^a, Najeeb B. Said^{b,§} and Peter J. Garratt^b

^aNovartis Institute for Medical Sciences, 5 Gower Place, London WC1E 6BN, U.K.

^bDepartment of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, U.K.

Current Addresses:-

[†]NEN Life Science Products, DuPont UK Ltd., Wedgewood Way, Stevenage, Hertfordshire, SG1 4QN, U.K.

[‡]Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 4AB, U.K.

[§]Instituto de Quimica Organica, CSIC, Juan de la Cierva 3, E-28006, Madrid, Spain.

Received 2 June 1998; accepted 5 January 1999

Abstract: The Bradykinin B₂ receptor antagonist HOE 140 (D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg) has been used as a template for the *de novo* design and synthesis of a small number of non-peptide lead compounds based on the 1,4-benzodiazepin-2-one framework. Two of the compounds have been found to exhibit moderate K_i values of 8.9 and 9.2 μM at the human Bradykinin B₂ receptor. © 1999 Elsevier Science Ltd. All rights reserved.

Elevated levels of the endogenous hormonal nonapeptide Bradykinin (BK; Arg¹-Pro²-Pro³-Gly⁴-Phe⁵-Ser⁶-Pro⁷-Phe⁸-Arg⁹) have been implicated in numerous pathophysiological processes¹ many of which are believed to be mediated by the B₂ class of BK receptors. An antagonist of the BK B₂ receptor would therefore offer great potential for therapeutic intervention, particularly in pain and inflammation.^{2,3}

There has been significant progress in the development of potent peptidic B₂ antagonists, the best example being HOE 140 (Icatibant; D-Arg⁰-Arg¹-Pro²-Hyp³-Gly⁴-Thi⁵-Ser⁶-D-Tic⁷-Oic⁸-Arg⁹) a second-generation antagonist from the Hoechst group.⁴ However, the well-documented disadvantages of peptides as therapeutic agents⁵ have prompted a search for low-molecular weight non-peptide antagonists,⁶ with superior oral bioavailability and metabolic stability properties.


A rational approach toward the *de novo* design of a non-peptide antagonist may be envisaged if the biologically relevant conformation of a peptide antagonist were known. The conformations of HOE 140⁷ and BK⁸ in a membrane-like surrounding have been determined *via* NMR spectroscopy in SDS micelles, and are characterized by C-terminal β-turns comprising residues 6-9. The β-turn is a structural motif that has been postulated in many other cases for the biologically active form of linear peptides.⁹ As a putative recognition element,¹⁰ it can be assumed that the precise spatial orientation of the side chains is important in the presentation of pharmacophoric information to the receptor.¹¹

* Corresponding author. Email: ed.dziadulewicz@pharma.novartis.com; Fax: +44 (0)171 387 4116

Dedicated to Professor Dieter Seebach on the occasion of his 60th birthday

With its similar molecular dimensions, the benzodiazepine (BZD) nucleus has been shown to be a good mimetic of a number of β -turn types,¹² and often incorporates a second aromatic ring (in effect, an embedded diphenylmethyl or benzhydryl group). In the literature, there is precedent for a three-point binding model for small molecule interactions with peptide receptors,¹³ and Ariens has proposed¹⁴ that one of these sites recognizes the "double-ring" motif exemplified by the benzhydryl group, which is often conformationally constrained from intramolecular hydrophobic clustering or hydrophobic collapse.¹⁵ Coupled with the fact that, as a drug class, BZDs are known to have good oral bioavailability and to be well tolerated, we determined to combine these observations and herein report our initial results in the *de novo* design of novel BZD-based lead compounds displaying affinity for the human BK B₂ receptor.

In the design of their β -turn peptidomimetic scaffold, Ripka, De Lucca, and co-workers¹² placed the benzodiazepinone core in the ($i + 2$)th corner of a number of β -turn types. Acting as an internal β -turn mimetic,¹⁶ the BZD core is then able to radiate its substituents along the corresponding peptide side chain trajectories, with the lactam moiety more or less superimposed onto the peptide bond between amino acid residues $i + 2$ and $i + 3$. Figure 1 illustrates the overlay with respect to our peptide template, HOE 140, and highlights the amino acid residues we chose to mimic assuming that this conformation is maintained in the receptor-bound state.¹⁷



By utilizing the phenyl substituent at C5 as the $i + 1$ binding determinant (retaining the "double-ring" motif¹⁴), the subsequent introduction of additional functionality would be immediately facilitated. A C3-hydrophobic mimic of the $i + 2$ residue would easily be incorporated by use of an appropriate amino acid, whereas a mimic of the Arg⁹ side chain could conceivably be elaborated from N1 by alkylation with a suitable electrophile. Alternatively, the $i + 3$ position could comprise a carboxylic acid function in accordance with peptide structure-activity requirements.¹⁸

The correct orientation of the BZD substituents is also an important design aspiration. In order to accommodate the C3-substituent in a *pseudo*-equatorial position,¹² the seven-membered ring is puckered in such a way that the C5-substituent is projected on one side of the lactam plane in the (*S*)-enantiomer and on the opposite side in the antipode. Only the (*R*)-BZD enantiomer is revealed by molecular modelling to be capable of maintaining all three binding determinants in the appropriate positions. Despite the aforementioned stereochemical bias in this paradigm, it was prudent and expedient to evaluate racemic mixtures at the outset of the lead finding process. In this way the (*S*)-enantiomers would not be disqualified from revealing any antagonistic activity arising from an alternative mode of binding. Finally, the benzyl side chain of phenylalanine was initially chosen as the C3-substituent. Use of an aromatic amino acid to represent the residue Oic⁸, an aliphatic analogue of proline, was deemed acceptable given the occurrence of the former at the corresponding *i* + 2 position in the first-generation BK antagonists.¹⁹

Racemic 1,4-benzodiazepin-2-one compounds **3**, **4b-c**, **5b-c**, **7** and **9** were synthesized according to Schemes 1 and 2. In order to mimic the Arg⁹ basic side chain of HOE 140, a four-carbon atom chain length was maintained for the distance separating the BZD lactam nitrogen atom and the basic terminal group. Table 1 summarizes the binding affinities of this initial set of compounds against the human BK B₂ receptor expressed as K_i values.

Table 1. Human Bradykinin B₂ Receptor Affinities (K_i) of BZD Ligands.^a

| compd. ^b | K _i (μM) | compd. ^b | K _i (μM) | compd. ^b | K _i (μM) |
|-----------------------|-----------------------|--------------------------------------|---------------------|--------------------------------------|---------------------|
| 3 ^c | >100 | 5b | >100 | (<i>S</i>)- 5c ^e | 15.8 ± 7.6 |
| 4b | (26 ± 5) ^d | 5c | 8.9 ± 4.3 | 7 | >100 |
| 4c | 21.3 ± 4.0 | (<i>R</i>)- 5c ^e | 11.9 ± 3.8 | 9 | 9.2 ± 5.4 |

^a [³H]-BK binding assay. K_i values were determined from concentration-response curves at the human B₂ BK receptor (membranes from Cos-7 cells expressing the human B₂ receptor). The values shown are the mean ± s.e.m. (n ≥ 3).


^b All the compounds gave satisfactory ¹H NMR, mass spectra, and elemental microanalyses.

^c Apart from **3**, all compounds were isolated as amorphous, TFA-containing solids after preparative HPLC.


^d Figure in parentheses is the % inhibition at 10 μM (in this case the K_i was not determined).

^e (*R*)-**5c**: [α]_D = +8.9° (c = 1.007 in MeOH); (*S*)-**5c**: [α]_D = -8.7° (c = 1.01 in MeOH).

Modest B₂ receptor affinity was revealed for this compound class once a basic side chain was appended to the BZD core (compounds **4b** and **4c**). Replacement of the flexible butyl linker chain with the correspondingly constrained benzyl one abolishes activity completely (compound **5b**), presumably due to the reduced basicity of the terminal nitrogen atom which is rendered anilinic in this example. Elaboration of the aniline **5b** to the guanidine **5c** enhances inhibitory potency, although there is still little to distinguish the relative affinities of **4c**



Scheme 1. Reagents and conditions: (a) (i) *N*-methylmorpholine, THF, -15°C, isobutyl chloroformate, (ii) 2-aminobenzophenone; (b) (i) HCl(g), EtOAc, 0°C, (ii) MeOH, 1M NaOH; (c) (i) *t*-BuOK in THF (1M), THF, 0°C, N₂, (ii) *N*-(4-bromobutyl)phthalimide (for 4a) or 3-nitrobenzyl bromide (for 5a, (R)-5a, (S)-5a); (d) H₂NNH₂, EtOH; (e) SnCl₂·2H₂O, EtOAc, 70°C, 16h; (f) (i) *N,N'*-di-Boc-thiourea, HgCl₂, DMF, 18h, (ii) TFA, CH₂Cl₂.



Scheme 2. Reagents and conditions: (a) (i) *t*-BuOK in THF (1M), THF, 0°C, N₂, (ii) ethyl bromoacetate; (b) 1M KOH, EtOH, rt; (c) (i) 1-iodo-4-nitrobenzene, Cu powder, NaOAc, DMF, 150°C, 4h, (ii) 20h, rt; (d) SnCl₂·2H₂O, EtOAc, 70°C, 16h; (e) (i) *N,N'*-di-Boc-thiourea, HgCl₂, DMF, 20h, (ii) TFA, CH₂Cl₂.

and **5c**, despite the greater entropic penalty one might expect for the former. According to peptide structure-activity relationships, the presence of a free C-terminal carboxylic acid function is essential for high-affinity binding of the peptide ligands.¹⁸ However, this observation did not extrapolate to a workable design feature in the present series of compounds (compound **7**), although other chain lengths would have to be assessed before discounting this avenue altogether.

Compound **9** represents the most conformationally restricted example, and is accorded a similar binding affinity to that of **5c** (9.2 μM and 8.9 μM respectively) suggesting a common orientation of the basic moieties in their interaction with complementary receptor components. Analysis of **5c** in a $^{45}\text{Ca}^{2+}$ efflux functional assay (SK-N-SH human neuroblastoma cells) revealed that this compound, active in a radioligand binding assay, was also able to antagonize the functional response to BK, with an IC_{50} of $2.3 \pm 1.1 \mu\text{M}$.

As mentioned earlier, adherence to the overlay model should manifest itself as preferential accommodation of one enantiomer, the higher *in vitro* activity expected to reside in the (*R*)-form. The individual enantiomers of **5c** were synthesized from (*R*)- and (*S*)-*N*-Boc phenylalanine (Scheme 1), monitoring stereochemical integrity by chiral HPLC. Unfortunately, (*R*)-**5c** and (*S*)-**5c** had similar affinity profiles for the B_2 receptor (Table 1), suggesting that the amino acid side chains are not differentially perceived by the immediate binding site environment. The degree of activity of **5c**, (*R*)-**5c** and (*S*)-**5c** is more reminiscent of a two-point binding interaction, and indicates that the spatial relationship between the β -turn-mimicking side chains is not optimal. It therefore remains an important objective of ours not only to advance *in vitro* activity, seeking an improvement in the eudismic ratio as confirmation of the current design requirements, but also to ascertain the selectivity of this compound class at a number of other receptors.²⁰

We have successfully designed novel human Bradykinin B_2 receptor lead compounds (**5c** and **9**) using a generalized BZD scaffold as a β -turn mimetic. Although different G protein-coupled receptor antagonists may bind in different receptor regions, the presence of the guanidine residue and the hydrophobic BZD core bears a structural resemblance to the positively charged terminal arginine residue (Arg^9) and the prominent hydrophobic residues (D-Tic^7 and Oic^8) in HOE 140 which we have used as a template in the lead finding process.²¹ In describing the direct conversion of a second generation peptide antagonist into a non-peptide lead,²² this communication provides another example of certain “privileged structures” furnishing useful leads in the search for new receptor-binding ligands. Encouraged by these early results, further evaluation of various side chains and the BZD core architecture has been pursued and will form the basis of a future publication.

Acknowledgments. N. B. S. gratefully acknowledges financial support from the Engineering and Physical Sciences Research Council (CASE award no. 93304817), and would like to thank Dr Roger Wigglesworth for providing laboratory facilities at NIMS. We would also like to thank Dr Chris Snell for preliminary molecular modelling studies. We are indebted to Dr Natarajan Subramanian (Novartis, Basel) for conducting the receptor selectivity screens.

References and Notes

1. Kyle, D. J.; Burch, R. M. *Curr. Opin. Invest. Drugs* **1993**, *2*, 5-20.
2. Proud, D.; Kaplan, A. P. *Ann. Rev. Immunol.* **1988**, *6*, 49-84.
3. Farmer, S. G.; Burch, R. M. In *Bradykinin Antagonists: Basic and Clinical Research*; Burch, R. M., Ed.; Marcel Dekker: New York, 1990; pp 1-31.
4. Hock, F. J.; Wirth, K.; Albus, U.; Linz, W.; Gerhards, H. J.; Wiemer, G.; Henke, S.; Breipohl, G.; König, W.; Knolle, J.; Schölkens, B. A. *Br. J. Pharmacol.* **1991**, *102*, 769-773.
5. Banga, A. K.; Chien, Y. W. *Int. J. Pharm.* **1988**, *48*, 15-50.
6. (a) Salvino, J. M.; Seoane, P. R.; Douthy, B.D.; Awad, M. M. A.; Dolle, R. E.; Houck, W. T.; Faunce, D. M.; Sawutz, D. G. *J. Med. Chem.* **1993**, *36*, 2583-2584. (b) Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Imai, K.; Inamura, N.; Asano, M.; Hatori, C.; Katayama, A.; Oku, T.; Tanaka, H. *J. Med. Chem.* **1998**, *41*, 564-578. (c) Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Inamura, N.; Asano, M.; Hatori, C.; Sawai, H.; Oku, T.; Tanaka, H. *J. Med. Chem.* **1998**, *41*, 4053-4061. (d) Abe, Y.; Kayakiri, H.; Satoh, S.; Inoue, T.; Sawada, Y.; Inamura, N.; Asano, M.; Aramori, I.; Hatori, C.; Sawai, H.; Oku, T.; Tanaka, H. *J. Med. Chem.* **1998**, *41*, 4062-4079 and 4587-4598.
7. Guba, W.; Haessner, R.; Breipohl, G.; Henke, S.; Knolle, J.; Santagada, V.; Kessler, H. *J. Am. Chem. Soc.* **1994**, *116*, 7532-7540.
8. Lee, S. C.; Russell, A. F.; Laidig, W. D. *Int. J. Peptide Protein Res.* **1990**, *35*, 367-377.
9. Rose, G. D.; Gierasch, L. M.; Smith, J. A. *Adv. Protein Chem.* **1985**, *37*, 1-109.
10. Stanfield, R. L.; Fieser, T. M.; Lerner, R. A.; Wilson, I. A. *Science* **1990**, *248*, 712-719.
11. Hruby, V. J. *Life Sci.* **1982**, *31*, 189-199.
12. Ripka, W. C.; De Lucca, G. V.; Bach II, A. C.; Pottorf, R. S.; Blaney, J. M. *Tetrahedron* **1993**, *49*, 3593-3628 and refs. therein.
13. Korolkovas, A.; Burckhalter, J. H. In *Essentials of Medicinal Chemistry*; Wiley: New York, 1976; pp 124-125.
14. Ariens, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. In *The Receptors: A Comprehensive Treatise*; O'Brien, R. D., Ed.; Plenum: New York, 1979; Vol. 1, pp 33-91.
15. Rich, D. H. In *Perspectives in Medicinal Chemistry*; Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Eds.; VHCA: Basel, 1993; pp 15-25.
16. Internal β -turn mimetics are molecules in which the mimetic skeleton approximately replaces the space that was occupied by the peptide backbone in the natural β -turn.
17. Kyle, D. J.; Blake, P. R.; Smithwick, D.; Green, L. M.; Martin, J. A.; Sinsko, J. A.; Summers, M. F. *J. Med. Chem.* **1993**, *36*, 1450-1460.
18. Stewart, J. M.; Woolley, D. W. *Nature (London)* **1965**, *207*, 1160-1161.
19. Stewart, J. M.; Vavrek, R. J. In *Bradykinin Antagonists: Basic and Clinical Research*; Burch, R. M., Ed.; Marcel Dekker: New York, 1990; pp 51-96.
20. The BZD scaffold described herein has previously been employed for the syntheses of CCK antagonists, among others. The selectivities of **5c** and **9** were assessed at a number of receptors (including A_1 , A_{2A} , α_1 , α_{2A} , α_{2B} , CCK_A, D₂, GABA_A, kainate). At concentrations up to 10 μ M, the compounds did not significantly affect (<20%) ligand binding to these receptors. At the same concentration, both compounds inhibited ligand binding to CCK_B by approximately 25%.
21. Filizola, M.; Llorens, O.; Carteni-Farina, M.; Perez, J. J. *Bioorg. Med. Chem.* **1998**, *6*, 1491-1500.
22. During the course of our work a similar, non-BZD approach was published: Goodfellow, V. S.; Laudeman, C. P.; Gerrity, J. I.; Burkard, M.; Strobel, E.; Zuzack, J. S.; McLeod, D. A. *Molecular Diversity* **1996**, *2*, 97-102.